News | November 10, 2021
US govt places additional order of 1.4 million courses of molnupiravir
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
New bioinformatic workflow advances analysis capabilities for whole-exome assessment and interpretation
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Subscribe To Our Newsletter & Stay Updated
